Trial Details

COMPLETED
Basic Information
Clinical ID c3114
Identifier NCT02513459
Trial Title A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
Trial URL Visit Original Page
Study Information
Study Results

YES

Conditions Crohn Disease
Interventions DRUG: Risankizumab 600 mg IV|DRUG: Risankizumab 180 mg SC
Participant Information
Sponsor AbbVie
City Chevy Chase
Country/Region United States
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE2
Time Information
Start Date 2015-09-16
Primary Completion Date 2019-06-19
Completion Date 2019-06-19